Johns Hopkins ABX Guide
Ciprofloxacin
Ciprofloxacin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Use of ciprofloxacin for acute sinusitis and acute uncomplicated UTIs should be avoided due recent FDA warning (Boxed warning) regarding serious and potentially permanent side effects (tendonitis and tendon rupture, peripheral neuropathy and CNS side effects). FDA safety warning regarding fluoroquinolone use.
- Lower respiratory tract infections
- Complicated intra-abdominal infections. Note: IDSA/SIS guidelines recommend ciprofloxacin in combination with metronidazole for community-acquired intra-abdominal infections and biliary tract infections. Due to high rates of E. coli resistance in many communities empiric use for health care-associated complicated infections is not recommended unless hospital surveillance indicates >90% susceptibility of E. coli to ciprofloxacin[3].
- Infectious diarrhea
- Uncomplicated cervical and urethral N. gonorrhoeae (note: high resistance rates make fluoroquinolones no longer recommended agent)
- Typhoid fever
- Lower respiratory tract infections
- Complicated intra-abdominal infections
- Infectious diarrhea
- Chronic bacterial prostatitis
- Skin and soft-tissue infections
- Bone and joint infections
- Complicated urinary tract infections and pyelonephritis in pediatric patients
- Inhalational anthrax postexposure in adult and pediatric patients
- Plague in adult and pediatric patients
- Bacterial conjunctivitis (ophthalmic ointment)
- Bacterial conjunctivitis and corneal ulcers (ophthalmic solution)
- Acute otitis externa (otic suspension)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Empiric therapy for neutropenic fever (in combination amoxicillin/clavulanate) in low-risk patients.
- Meningitis caused by Gram-negative organisms in penicillin allergic patients.
- Chron’s flare
- Spontaneous bacterial peritonitis (SBP) prophylaxis
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Use of ciprofloxacin for acute sinusitis and acute uncomplicated UTIs should be avoided due recent FDA warning (Boxed warning) regarding serious and potentially permanent side effects (tendonitis and tendon rupture, peripheral neuropathy and CNS side effects). FDA safety warning regarding fluoroquinolone use.
- Lower respiratory tract infections
- Complicated intra-abdominal infections. Note: IDSA/SIS guidelines recommend ciprofloxacin in combination with metronidazole for community-acquired intra-abdominal infections and biliary tract infections. Due to high rates of E. coli resistance in many communities empiric use for health care-associated complicated infections is not recommended unless hospital surveillance indicates >90% susceptibility of E. coli to ciprofloxacin[3].
- Infectious diarrhea
- Uncomplicated cervical and urethral N. gonorrhoeae (note: high resistance rates make fluoroquinolones no longer recommended agent)
- Typhoid fever
- Lower respiratory tract infections
- Complicated intra-abdominal infections
- Infectious diarrhea
- Chronic bacterial prostatitis
- Skin and soft-tissue infections
- Bone and joint infections
- Complicated urinary tract infections and pyelonephritis in pediatric patients
- Inhalational anthrax postexposure in adult and pediatric patients
- Plague in adult and pediatric patients
- Bacterial conjunctivitis (ophthalmic ointment)
- Bacterial conjunctivitis and corneal ulcers (ophthalmic solution)
- Acute otitis externa (otic suspension)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Empiric therapy for neutropenic fever (in combination amoxicillin/clavulanate) in low-risk patients.
- Meningitis caused by Gram-negative organisms in penicillin allergic patients.
- Chron’s flare
- Spontaneous bacterial peritonitis (SBP) prophylaxis
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 18, 2019
Citation
Avdic, Edina, and Paul A Pham. "Ciprofloxacin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540128/all/Ciprofloxacin.
Avdic E, Pham PA. Ciprofloxacin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540128/all/Ciprofloxacin. Accessed March 20, 2023.
Avdic, E., & Pham, P. A. (2019). Ciprofloxacin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540128/all/Ciprofloxacin
Avdic E, Pham PA. Ciprofloxacin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2023 March 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540128/all/Ciprofloxacin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ciprofloxacin
ID - 540128
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2019/10/18/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540128/all/Ciprofloxacin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
